Hematologic Malignancy clinical trials at UC Irvine
4 in progress, 3 open to eligible people
9-ING-41 in Patients With Advanced Cancers
open to eligible people ages 18 years and up
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Orange, California and other locations
HMPL-306 in Advanced Hematological Malignancies With mIDH
open to eligible people ages 18 years and up
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Orange, California and other locations
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
open to eligible people ages 18-70
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Orange, California
CB-Long-Term Safety Study (CB-LTSS)
Sorry, accepting new patients by invitation only
This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.
Irvine, California and other locations
Our lead scientists for Hematologic Malignancy research studies include Stefan Octavian Ciurea Jennifer Valerin, MD.
Last updated: